Nanomaterials in gene therapy and genome editing: challenges and emerging directions

Nanomaterials are redefining the landscape of gene and genome editing, yet their translation to clinical reality remains constrained by multiple unresolved challenges. While they provide structural and functional advantages for delivering nucleic acids and CRISPR/Cas systems across biological barriers, their behavior within living systems is often unpredictable, leading to issues such as off-target editing, immune activation, and inconsistent biodistribution. The design of nanocarriers, whether lipid-based, polymeric, inorganic, must therefore balance efficiency with safety, integrating physicochemical precision with biological adaptability. Recent advances in ionizable lipid nanoparticles demonstrate how fine-tuning charge, surface chemistry, and degradation kinetics can enhance endosomal escape and target specificity, but reproducibility and large-scale manufacturing continue to limit broader application. Moreover, polymeric and exosome-inspired systems promise modularity and targeted reuse, yet they demand clearer understanding of long-term biocompatibility and regulatory acceptance. The future of nanomaterial-enabled genome engineering depends not only on optimizing delivery vehicles but also on establishing predictive models of nano–bio interactions, harmonizing ethical oversight, and developing standardized evaluation pipelines that link nanoscale design to therapeutic outcomes.